All posts

Stock Market Update: Redline, Cardiol and Field Trip Health top the TSX

Shares of communications equipment maker Redline Communications (Redline Communications Stock Quote, Chart, News, Analysts, Financials TSX:RDL) are soaring Monday as investors digest some recent sales.

On Thursday, the company announced it had sold LTE equipment to an unnamed precious metals mining company in Nevada.

“Real-time data is becoming essential for operational visibility, worker safety, and live communications at remote sites throughout the mining industry,” said Reno Moccia, who is Redline’s Executive Vice President of Sales and Marketing. “Industrial-grade LTE is emerging as the platform infrastructure of choice for the future of mining. Redline’s private iLTE network enhances automation at mining sites by monitoring and controlling equipment without interruption; connecting personnel, vehicles and sensors; and improving safety and production uptime.”

The news follows on another sale to a customer operating a salt and minerals mine in Salt Lake City.

At press time, shares of Redline were up 27.7 per cent to $0.83.

Also making gains Monday was cardiovascular company Cardiol (Cardiol Stock Quote, Chart, News, Analysts, Financials TSX:CRDL), which today announced it would expand its Lancer trial into Brazil, Mexico and Canada. The Lancer trial is meant to test the efficacy and safety of the company’s cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19.

“COVID-19 remains an international crisis and there remains an urgent need to develop new therapeutics to address the immune-mediated inflammation that results from the virus, particularly in high-risk patients with cardiovascular disease,” said Cardiol Chairman Dr. Guillermo Torre-Amione. “With the expansion of the Lancer trial to include prominent clinical research centers in Brazil, Mexico, and Canada, we are now positioned to accelerate patient recruitment into the trial and expedite the path towards our goal of determining the cardioprotective properties of CardiolRx in COVID patients with pre-existing, or significant risk factors for, cardiovascular disease.”

Also posting gains today is psychedelic therapies company Field Trip Health (Field Trip Health Stock Quote, Chart, News, Analysts, Financials TSX:FTRP), which was up 6.1 per cent to $7.18 at press time. It’s been a strong month for FTRP, which closed October 4 and just $5.45.

Overall, the Toronto Stock Exchange was up 16.12 points to 20,944.22 at press time.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: crdlftrprdl
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

19 hours ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

20 hours ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

2 days ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

2 days ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

2 days ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

5 days ago